Table of Contents
A patent portfolio analysis New York in-house teams can put in front of a board treats patents as what Wall Street already treats them as — an asset class with a carrying cost, a risk profile and a market value. New York is the world’s financial capital and a U.S. headquarters city for finance, pharma, media and advertising technology, so the questions asked of a portfolio here are commercial before they are legal: What is it worth in an acquisition? Where are the gaps a competitor could file into? And which annuities bleeding cash every quarter should we stop paying? PerspireIP answers those questions for the R&D leaders and IP counsel running New York portfolios.
The work is landscape, gap, strength and valuation analysis — not litigation. It is the diligence that supports an M&A deal on Park Avenue, the schedule that lets a venture-backed founder show real IP to a Series B investor, and the maintenance-fee decision that keeps a large portfolio from quietly overspending at the USPTO year after year.
Why patent portfolio analysis New York deal teams start on the balance sheet
In most cities a portfolio review starts with the technology. In New York it starts with the transaction. The city is the global hub for mergers and acquisitions, private equity and venture capital, and patents are routinely the collateral, the diligence line item or the deal-breaker in those transactions. A buyer wants to know the target’s patents are valid, in force and actually cover the products; a lender wants to know they can be pledged; an investor wants proof the moat is real.
That framing changes what a study has to deliver. A landscape map is not an academic exercise here — it is an exhibit in a data room. A strength assessment is not a curiosity — it is a number that moves a purchase price. We build portfolio analysis that a corporate-development team, a fund’s investment committee or a CFO can act on, tied to the deal or the budget cycle that prompted it.
- M&A and PE diligence — validity, ownership chain, encumbrances and product coverage of a target’s patents before a bid
- Venture and growth financing — an honest read of whether the IP backs the founder’s story to a Series A/B investor
- IP as collateral — portfolio valuation to support patent-backed lending and asset pledges
- Board and budget reviews — a periodic strength, gap and cost picture for the CFO and the general counsel
Pruning maintenance-fee spend at the USPTO
The single fastest return a portfolio review delivers is usually a cut, not a filing. U.S. patents carry maintenance fees due at three fixed points after grant — 3.5, 7.5 and 11.5 years — and the fees escalate steeply across those tiers. For a large entity the schedule that took effect on 19 January 2025 is $1,600 at 3.5 years, $3,600 at 7.5 years and $7,400 at 11.5 years, an increase of roughly 7.5% over the prior fees. Small entities pay 60% less and micro entities 80% less, but the escalation curve is the same.
Miss a due date and there is a six-month grace period, but only with a surcharge — $540 for a large entity — and after that the patent lapses. Multiply the third-stage fee across a portfolio of hundreds of granted patents and the annual annuity bill runs into six or seven figures, much of it spent on patents that no longer read on a live product or a competitor.
A pruning analysis scores every asset against three tests before the next fee falls due: does it still cover a shipping product or a roadmap item, does it block a competitor, and would a buyer pay for it. Assets that fail all three are candidates to abandon at the next window. For a New York portfolio owner the exercise typically pays for itself many times over at the very first 11.5-year decision it informs.
The PTAB and the Federal Circuit as a portfolio-risk lens
Strength is not just how many claims you hold — it is how many survive a challenge. The USPTO’s Patent Trial and Appeal Board hears inter partes review, the administrative proceeding in which a challenger asks to cancel claims on novelty and obviousness over patents and printed publications. The Board institutes only where the petitioner shows a reasonable likelihood of prevailing on at least one claim, then decides on a preponderance of the evidence — a lower bar than the clear-and-convincing standard a district court applies. By statute a final written decision follows within twelve months of institution, so the whole proceeding runs faster and cheaper than court.
That makes IPR the right stress test for a portfolio. We grade each significant asset for its exposure: how crowded is the prior art, how broad are the independent claims, how vulnerable is the family to an obviousness combination. A patent that would not survive an IPR is worth less in a deal and dangerous to assert, and a buyer’s counsel will find that out — better to know first.
Every U.S. patent appeal, whether from a district court or from the PTAB, is decided by a single court: the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. That concentration means the case law on claim construction, obviousness and eligibility is uniform nationwide, so a New York portfolio can be graded against one coherent body of precedent rather than a patchwork of regional rules.
What New York’s finance, pharma, media and fashion portfolios look like
New York’s patent base is unusually broad because its economy is. The city is the U.S. capital of finance and fintech, and the portfolios reflect it: payments, trading systems, risk analytics and data infrastructure from banks, exchanges, card networks and market-data houses — the world of Goldman Sachs, Bloomberg, Mastercard and American Express. Much of that estate is software and business-method patents, which carry their own eligibility risk under Section 101 and reward a landscape read.
- Finance and fintech — payments, trading, risk and market-data patents, heavy on software and method claims and on Section 101 eligibility questions
- Pharmaceuticals and life sciences — Pfizer runs its global headquarters from The Spiral at 66 Hudson Boulevard in Hudson Yards; small-molecule, biologic and formulation families where a single patent can carry a product
- Media, advertising and adtech — content delivery, recommendation, ad-targeting and rights-management patents from the city’s publishing and Madison Avenue base
- Fashion and retail technology — design, materials, e-commerce and supply-chain inventions from New York’s fashion-tech and DTC sector
Each sector hides its value in a different place. A pharma portfolio may live or die on one composition-of-matter patent and its term extension; a fintech estate is a thicket of narrower method patents whose strength is collective. A patent portfolio analysis New York owners rely on has to read each estate on its own terms rather than counting patents.
Landscape, gap and white-space analysis, plus standards exposure
The offensive side of portfolio work is finding what you do not yet own. A landscape maps the patents held by you and your competitors across a technology area; a gap or white-space analysis then shows where protectable, commercially useful inventions sit unclaimed — the space your R&D leaders should be filing into before a rival does.
For New York’s finance, media and hardware-adjacent companies, standard-essential patents and FRAND exposure are a second landscape question. If a product implements a standard — a wireless, video-codec or payments standard — the portfolio has both a liability (patents others declare essential) and potentially an asset (your own declared-essential patents). Mapping which of your patents read on a standard, and which third-party SEPs read on your products, is core portfolio intelligence, not litigation.
- Competitive landscape maps — who holds what across your technology space, by assignee, claim scope and filing trend
- Gap and white-space analysis — unclaimed, protectable ground to direct the next filing program
- Strength and coverage scoring — how well the portfolio actually covers the products and roadmap
- SEP and FRAND mapping — declared-essential exposure and opportunity against the standards your products touch
Where New York patent disputes land: SDNY, EDNY and venue
Portfolio risk is partly forum risk, so a New York owner should know where its patents would be litigated. Suits in Manhattan and the Bronx are filed in the U.S. District Court for the Southern District of New York, seated at the Daniel Patrick Moynihan U.S. Courthouse, 500 Pearl Street; Brooklyn, Queens and Long Island fall in the Eastern District of New York. The two districts share a common set of Local Patent Rules, adopted on 8 April 2013 and deliberately concise — only a few pages — which structure infringement, validity and unenforceability cases from the initial scheduling conference forward.
Whether a company can even be sued here is a venue question. Under the Supreme Court’s decision in TC Heartland, a domestic corporation can be sued for patent infringement only where it is incorporated or where it has a regular and established place of business and has infringed. A New York-headquartered business with offices, labs or data centers in the district can properly be sued — or assert — in the SDNY or EDNY, a fact that belongs in any portfolio’s risk map.
Patent validity and infringement are exclusively federal questions, so there is no state-court patent venue in New York, and every appeal runs to the Federal Circuit rather than the Second Circuit. We flag which assets are most exposed to a venue-anchored assertion, so the portfolio can be strengthened or pruned before a dispute rather than during one.
How PerspireIP builds a portfolio analysis you can act on
Every engagement follows the same disciplined path, scaled to whether you are prepping a data room, defending a budget or planning next year’s filings. We inventory the portfolio, verify legal status and ownership, map each asset to products and competitors, grade strength and PTAB exposure, and price the estate for the transaction or decision that prompted the review.
- Full inventory with legal-status, term and maintenance-fee timeline for every asset
- Product-to-patent coverage mapping and a claim-strength score across the estate
- PTAB-risk grading of the significant assets against the prior art
- Landscape, gap and white-space maps, with SEP and FRAND exposure where relevant
- Maintenance-fee pruning recommendations tied to the next 3.5, 7.5 and 11.5-year windows
- A valuation view for M&A, financing or collateral, delivered as data-room-ready exhibits
We work alongside your in-house IP team, corporate-development group or outside counsel as a specialist analysis partner, deliver to your deal or budget calendar, and keep every engagement confidential. Whether you need a one-time diligence study before a New York acquisition, an annual portfolio health check for the board, or an ongoing pruning and landscaping program, we scale to fit. Send us the assignee name or a patent list and we will scope a patent portfolio analysis New York project within one business day.
IP Landscape & Resources in New York
Key intellectual-property authorities and venues relevant to New York:
- United States Patent and Trademark Office (USPTO) — grants U.S. patents and sets the maintenance-fee schedule due at 3.5, 7.5 and 11.5 years that drives portfolio pruning decisions
- USPTO Patent Trial and Appeal Board (PTAB) — hears inter partes review, the preponderance-standard proceeding used to grade how well portfolio claims would survive a validity challenge
- U.S. Court of Appeals for the Federal Circuit — the single appellate court for all U.S. patent appeals, from the district courts and the PTAB, giving portfolios one uniform body of precedent
- World Intellectual Property Organization (WIPO) — PATENTSCOPE — global patent-family and publication data used for landscape, gap and white-space analysis across jurisdictions
Request a Patent Portfolio Analysis in New York
Request a Patent Portfolio Analysis in New York
Get a landscape, gap, strength and valuation study built for a New York deal, board review or filing program — with maintenance-fee pruning tied to your next USPTO windows and a PTAB-risk read on the assets that matter. Send us the assignee name or a patent list and we will scope the work within one business day.
Explore related PerspireIP services: Patent Portfolio Analysis services · IP services in the United States · patent invalidation · prior art litigation search · patent infringement analysis · patent market research.
Frequently Asked Questions
What is a patent portfolio analysis, and how is it different from litigation work?
A patent portfolio analysis is a commercial and strategic review of the patents a company owns or is considering acquiring — a landscape of the competitive field, a gap or white-space map of what is unclaimed, a strength and coverage score against the products, and a valuation for a deal or a board. It is diligence and strategy, not enforcement: we are not litigating a case, we are telling you what the estate is worth, where it is weak, and what to file, keep or abandon. For New York clients that usually supports an M&A transaction, a financing, or the annual maintenance-fee budget.
How does a portfolio review cut USPTO maintenance-fee spend?
U.S. patents carry maintenance fees at 3.5, 7.5 and 11.5 years after grant, and they escalate — for a large entity the 2025 schedule is $1,600, then $3,600, then $7,400, with a $540 surcharge in the six-month grace period. Across a large portfolio that is a six- or seven-figure annual bill, much of it on patents that no longer cover a product or block a competitor. A pruning analysis scores each asset before its next window against product coverage, competitive value and resale value, so you stop paying for the assets that fail all three.
Why grade a portfolio against the PTAB?
Because a patent’s real strength is whether its claims survive a challenge, and the fastest challenge is an inter partes review at the USPTO’s Patent Trial and Appeal Board. The Board institutes on a reasonable likelihood of prevailing and decides on a preponderance of the evidence — a lower bar than a district court — with a final written decision within twelve months of institution. Grading each significant asset for prior-art crowding and claim breadth tells you which patents are safe to assert or sell and which a buyer’s counsel will discount.
Which New York sectors do you most often analyze?
Finance and fintech lead — payments, trading, risk and market-data patents from the banks, exchanges and card networks headquartered here, much of it software subject to Section 101 eligibility questions. Pharmaceuticals and life sciences are a close second, anchored by companies such as Pfizer, whose global headquarters sits in The Spiral at Hudson Yards. Media, advertising technology, and fashion and retail technology round out a portfolio base that is unusually broad for a single city, and each estate has to be read on its own terms.
Can you map our standard-essential patent and FRAND exposure?
Yes, and for New York’s finance, media and connected-hardware companies it is often the most valuable part of the review. If your products implement a standard, we map which third-party patents are declared essential and read on you — a liability — and which of your own patents read on the standard and could be declared essential — an asset. That SEP and FRAND picture is portfolio intelligence that informs licensing and valuation, and it sits alongside the landscape and gap analysis rather than being a separate litigation exercise.
Where would our New York patents be litigated if a dispute arose?
Manhattan and Bronx suits go to the U.S. District Court for the Southern District of New York at 500 Pearl Street; Brooklyn, Queens and Long Island fall in the Eastern District of New York. The two districts share concise Local Patent Rules adopted in 2013. Under TC Heartland a domestic company can be sued only where it is incorporated or has a regular, established place of business and has infringed, and every patent appeal goes to the Federal Circuit — all facts we fold into a portfolio’s risk map so you can strengthen or prune exposed assets in advance.
How do you support an M&A or venture diligence timeline?
We work to the deal calendar. For a buyer or investor we verify legal status, ownership chain and encumbrances, confirm the target’s patents actually cover the products, grade PTAB exposure, and deliver a valuation view as data-room-ready exhibits, typically inside the diligence window. For a company raising capital we build the same picture from the sell side so the IP story you show a Series A or B investor holds up under scrutiny. Send the assignee name or a patent list and we will scope the work within one business day.